search icon

    Market Snapshot

    • S&P Futures

      3,809.5

    • Dow Futures

      30,868

    • Nasdaq Futures

      11,633.25

    blog search icon

    Actinium Pharmaceuticals, Inc.

    (AMEX:ATNM)

    $4.81

    $-0.16

    -3.22%

    Actinium Pharmaceuticals, Inc. Chart

    ATNM Stock Price Today

    Actinium Pharmaceuticals, Inc. (ATNM) stock declined over -3.22% intraday to trade at $4.81 a share on AMEX. The stock opened with a loss of -4.75% at $4.87 and touched an intraday high of $5.015, falling -3.22% against the last close of $4.97. The stock went to a low of $4.8 during the session.

    Stock Snapshot

    $4.97

    Prev. Close

    116.64 Million

    Market Cap

    $4.8

    Day Low

    $4.87

    Open

    22.14 Million

    Number of Shares

    $5.015

    Day High

    -

    P/E ratio

    -1.14

    EPS (TTM)

    3.52

    Cash Flow per Share

    3.39

    Free Float in %

    3.64

    Book Value

    122,698

    Volume

    Actinium Pharmaceuticals, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-06-30$4.87$5.015$4.8$4.81122,698
    2022-06-29$5.05$5.05$4.89$4.97121,700
    2022-06-28$5.15$5.18$5$5.03155,000
    2022-06-27$5.12$5.19$5$5.16117,900
    2022-06-24$5.21$5.29$5.094$5.11221,200
    2022-06-23$5.2$5.29$5.17$5.21124,700
    2022-06-22$5.2$5.37$5.115$5.21176,800
    2022-06-21$5.33$5.37$5.2$5.3172,300
    2022-06-17$5.21$5.397$5.06$5.16199,800
    2022-06-16$5.02$5.18$4.85$5.17121,500

    Contact Details

    275 Madison Avenue
    7th Floor
    New York, NY 10016
    United States

    Webiste:ATNM

    646 677 3870

    Company Information

    Employees-

    Beta0.32

    Sales or Revenue1.14 Million

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

    Frequently Asked Questions

    icon

    What is the current Actinium Pharmaceuticals, Inc. (ATNM) stock price?

    Actinium Pharmaceuticals, Inc. (AMEX: ATNM) stock price is $4.81 as of the last check on Thursday, June 30. During the trading session, ATNM stock reached the peak price of $5.015 while $4.8 was the lowest point it dropped to.

    icon

    ATNM's industry and sector of operation?

    The AMEX listed ATNM is part of Biotechnology industry that operates in the broader Health Care sector. Actinium Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies.

    icon

    Who are the executives of ATNM?

    Mr. Sandesh C. Seth M.B.A., M.S., MBA
    Chairman & CEO
    Mr. Steven O'Loughlin BS
    CFO & Corp. Sec.
    Dr. Paul Diamond Esq., Ph.D.
    VP of Patent & Legal Counsel
    Dr. David Gould
    Sr. VP of Corp. Devel. & Corp. Affairs

    icon

    What is the ATNM stock price today?

    ATNM stock traded closed the last session at $4.81, which is $-0.16 or -3.22% lower than its previous close of $4.97. ATNM's current trading price is 9.07% lower than its 52-week high of $10.30 where as its distance from 52-week low of 4.41% is -53.30%.

    icon

    How many employees does ATNM have?

    Number of ATNM employees currently stands at -. ATNM operates from 275 Madison Avenue, 7th Floor, New York, NY 10016, United States.

    icon

    Link for ATNM official website?

    Official Webiste of $ATNM is: https://www.actiniumpharma.com

    icon

    How do I contact ATNM?

    ATNM could be contacted at ATNM operates from 275 Madison Avenue, 7th Floor, New York, NY 10016, United States, or at phone #646 677 3870 and can also be accessed through its website.

    icon

    How many shares of ATNM are traded daily?

    ATNM stock volume for the day was 122,698 shares while in the previous session number of ATNM shares traded was 122,698 . The average number of ATNM shares traded daily for last 3 months was 905.7 Thousands.

    icon

    How much did ATNM change today?

    The percentage change in ATNM stock occurred in the recent session was -3.22% while the dollar amount for the price change in ATNM stock was $-0.16.

    icon

    What price range ATNM stock been trading in?

    In the recent session, the day high for ATNM stock was $5.015 while the low for ATNM stock touched on the day was $4.8.

    icon

    What is the market cap of ATNM currently?

    The market value of ATNM currently stands at 116.64 Million with its latest stock price at $4.81 and 22.14 Million of its shares outstanding.